TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: ACUTAAS · data 2026-11-01
Acutaas Chemicals Ltd
In plain words
Price: at or near its 52-week high.
Delivery: 40.7% of traded shares were kept for delivery over the last 10 sessions, against 49.5% over the last 60.
Latest results: a net profit of ₹125 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,593 cr |
| Net profit (last 12 months) | ₹439 cr |
| Sales growth, 3 years (yearly) | 29.5% |
| Profit growth, 3 years (yearly) | 62.3% |
At a glance
Promoters 32.7%, pledged 0.0%, institutions 41.2%.
P/E 75.0, P/B 17.6, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 24.0%, ROCE 28.9%, operating margin 36.5%: how much profit it earns on the money it uses.
Debt/equity 0.02, Profit growth 62.3% and sales growth 29.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (24.0%).
- Healthy operating margin (36.5%).
- Profit grew 62.3% a year over 3 years.
- Expensive on earnings (P/E 75.0).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
ACUTAAS Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹436.92 crore.
Net profit was ₹125.17 crore.
Operating margin was 40.3%.
EPS was ₹15.29.
ACUTAAS के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹436.92 करोड़।
शुद्ध मुनाफ़ा: ₹125.17 करोड़।
ऑपरेटिंग मार्जिन: 40.3%।
EPS: ₹15.29।
ACUTAASના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹436.92 કરોડ.
ચોખ્ખો નફો: ₹125.17 કરોડ.
ઓપરેટિંગ માર્જિન: 40.3%.
EPS: ₹15.29.
Written from the filed numbers. Not a recommendation.
Smart-money activity
41/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 13/30: Delivery 34.2% over the last 20 sessions vs 49.8% in the 40 before (0.69x); shares delivered per day 1.94x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 15 schemes hold it, about ₹673 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 14/15: Verdict "Sustained", sustained score 92/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend ● Split
- 27 Oct 26Results Q2 FY27 results: net profit ₹125.2 cr +10.8% next session
- 17 Sept 26Dividend Dividend ₹2.5 (ex-date) +2.9% next session
- 18 Sept 25Dividend Dividend ₹1.5 (ex-date) -1.1% next session
- 25 Apr 25Split Split: face value ₹10 → ₹5 (ex-date)
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹437 cr | ₹125 cr | — | 40.3% | 15.29 |
| Jun 2024 | ₹177 cr | ₹14 cr | — | 16.7% | 3.67 |
| Sept 2023 | ₹172 cr | ₹-19 cr | — | 14.4% | -4.67 |
| Dec 2022 | ₹152 cr | ₹22 cr | — | 20.2% | 6.28 |
Shareholding trend
| Holder | Jun 2026 | Mar 2026 |
|---|---|---|
| Promoters | 32.66% | 32.66% |
| Foreign institutions (FII) | 21.61% | 19.48% |
| Domestic institutions (DII) | 19.56% | 19.60% |
| Mutual funds | 14.17% | 13.86% |
| Retail investors | 13.44% | 14.81% |
| Number of shareholders | 1,25,569 | 1,12,939 |
Common questions
What was Acutaas Chemicals Ltd's latest quarterly profit?
Acutaas Chemicals Ltd reported a net profit of ₹125 cr for the quarter ended Sept 2026, on revenue of ₹437 cr.
How much do promoters hold in Acutaas Chemicals Ltd?
Promoters held 32.66% of Acutaas Chemicals Ltd at the end of Jun 2026, with 0.00% of promoter shares pledged.
Is Acutaas Chemicals Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Acutaas Chemicals Ltd's P/E ratio?
About 75, based on the last 12 months' earnings and a price of ₹4,003.6 (data 2026-11-01).
What is the 52-week high and low of Acutaas Chemicals Ltd?
The 52-week high is ₹4,032.2 and the 52-week low is ₹1,570.
Mutual funds holding Acutaas Chemicals Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 15 schemes holding about ₹673 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 5.03% | ₹295 cr |
| SBI Smallcap Fund | SBI Mutual Fund | 0.30% | ₹123 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.32% | ₹81 cr |
| SBI Innovative Opportunities Fund | SBI Mutual Fund | 0.90% | ₹46 cr |
| SBI Quality Fund | SBI Mutual Fund | 1.02% | ₹26 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.76% | ₹26 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 2.80% | ₹26 cr |
| Nippon India Nifty 500 Momentum 50 Index Fund | Nippon India Mutual Fund | 1.47% | ₹19 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.76% | ₹13 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 2.00% | ₹7 cr |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 1.53% | ₹7 cr |
| ADITYA BIRLA SUN LIFE BSE 500 MOMENTUM 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.15% | ₹1 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.76% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.26% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.76% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Acutaas Chemicals Ltd | ₹4,003.6 | ₹32,770 cr | 75 | 17.7 | 24% | 28.9% | 0.02 | +137.3% |
| GlaxoSmithKline Pharmaceuticals Limited | ₹2,494.3 | ₹42,073 cr | 39.6 | — | 49.1% | 52.8% | 0.01 | -5.9% |
| Emcure Pharmaceuticals Limited | ₹1,871.8 | ₹35,440 cr | 35.1 | — | 19.7% | 22.6% | 0.31 | +39.7% |
| Piramal Pharma Limited | ₹238.91 | ₹31,826 cr | — | 3.9 | -4% | 1.3% | 0.7 | +17.0% |
| Wockhardt Limited | ₹1,901.1 | ₹30,809 cr | 75.5 | — | 4.6% | 5.3% | 0.45 | +44.7% |
| Neuland Laboratories Ltd. | ₹19,700 | ₹25,276 cr | 50.8 | — | 21.4% | 23.8% | 0.16 | +27.1% |
Compare ACUTAAS with GLAXO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ACUTAAS in TickerKhoj →